Lymphoglobuline (equine anti-thymocyte globulin) / Sanofi - LARVOL DELTA

Thymoglobuline and grafalon show comparable transplant outcomes in patients with aplastic anemia undergoing allogeneic stem cell transplantation: A multicenter EBMT saawp study of 1603 patients (ASH 2025) - "Introduction:Rabbit anti-thymocyte globulin (ATG) is a key component of conditioning regimens for patients withaplastic anemia (AA) undergoing allogeneic hematopoietic stem cell transplantation (HSCT).Thymoglobuline (Thymo) is widely regarded as the standard formulation due to its extensive clinicaladoption and inclusion in international guidelines, while Grafalon (Grafa) is also commonly used inclinical practice. In this large, registry-based cohort of AA patients undergoing HSCT, no significant differences wereobserved in OS, GF, GVHD incidence, or GRFS between Thymo and Grafa. However, Grafalon dosageappeared to influence outcomes, particularly with respect to chronic GVHD. These findings support theclinical equivalence of both rabbit ATG formulations in the setting of HSCT and suggest that ATG selectioncan be guided by institutional preference or availability without compromising patient outcomes."

Clinical • Acute Graft versus Host Disease • Anemia • Aplastic Anemia • Bone Marrow Transplantation • Chronic Graft versus Host Disease • Graft versus Host Disease • Immunology • Transplantation

The impact of HLA loss of heterozygosity on outcome after haploidentical hematopoietic stem cell transplantation in hematological malignancies (ASH 2025) - "Allpatients received haplo-HSCT; pre-transplant disease status was CR (80.0%, n=36) or NR (20.0%, n=9).Conditioning regimens were busulfan (Bu)-cyclophosphamide (Cy) (66.7%), total body Irradiation (TBI)-Cy(17.8%), Bu-fludarabine (flu) (13.3%), or TBI-flu (2.2%). ATG-fresenius (ATG-F) or ATG-thymoglobuline(ATG-T) were used for GVHD prophylaxis... Second transplantation improves survival in patients experiencing relapse following haplo-HSCT who demonstrate HLA loss. Survival outcomes were independent of HLA loss pattern (haplotype vs.locus-specific) or extent (number of loci lost). Poor prognostic factors were pre-transplant NR status andthe use of TBI-based conditioning."

IO biomarker • Acute Lymphocytic Leukemia • Acute Myelogenous Leukemia • Bone Marrow Transplantation • Graft versus Host Disease • Hematological Malignancies • Hepatology • Immunology • Infectious Disease • Leukemia • Liver Failure • Lymphoma • Myelodysplastic Syndrome • Non-Hodgkin’s Lymphoma • Oncology • Transplantation • HLA-B • HLA-C • HLA-DQB1 • HLA-DRB1

Decreased Chronic GvHD with Post-Transplant Cyclophosphamide (PTCY) Compared to ATG in Patients with Myelofibrosis Allografted with Unrelated Donor: A Study from the Chronic Malignancies Working Party of the EBMT (ASH 2024) - "Background Prospective randomized trials have reported a benefit for anti-thymoglobuline (ATG)-based graft-versus-host disease (GvHD) prophylaxis in the setting of allogeneic hematopoietic stem cell transplantation (alloHSCT) using unrelated donors (UD)...Cox (cause-specific) proportional hazards models were used to obtain adjusted estimates of the effect of PTCY compared to ATG on all endpoints, with a predefined set of adjustment factors (age, DIPSS, donor HLA matching, prior ruxolitinib, comorbidity score, MF subtype (PMF vs sMF)) and a frailty term for transplant center...PTCY is a valid option and considering availability and costs of ATG this may offer a good choice/alternative for regions which do have difficulties to have access to ATG. However, engraftment remains an issue in this setting."

Clinical • Post-transplantation • Bone Marrow Transplantation • Chronic Graft versus Host Disease • Graft versus Host Disease • Immunology • Myelofibrosis • Oncology • Transplantation

Sequential Conditioning Regimen with Thiotepa, Clofarabine and Busulfan (TEC/CloB2A2) and Post-Transplant Cyclophosphamide in Adults with Refractory AML: A Retrospective Monocentric Study (ASH 2023) - "Recently, a combination of thiotepa, etoposide, cyclophosphamide (TEC) followed by fludarabine/busulfan/ATG (FB2A2) using any type of donor for refractory hematologic malignancies have shown some promising results (Dulery, 2018)...The TEC/CloB2A2 regimen consisted of Thiotepa 5 mg/kg at day(d)-13, Cyclophosphamide 400 mg/m²/d from d-12 to d-9 and Etoposide phosphate 100 mg/m²/d from d-12 to d-9, followed after 3 days of rest, by Clofarabine 30 mg/m²/d from d-5 to d-1, Busulfan 3,2 mg/kg/d d-5 and d-4 and Thymoglobuline 2,5 mg/kg/d d-3 and d-2. GVHD prophylaxis consisted of high-dose of post-transplant Cyclophosphamide (PTCY) 50 mg/kg/d at d+3 and d+5 in combination with mycophenolate mofetyl and cyclosporine starting at d+6...Six out of 8 CR/CRp patients received maintenance treatment after transplant to prevent relapse using 5'azacytidine alone in 1, 5 azacytidine+ donor lymphocyte infusion (DLI) in 2, DLI alone in 1... The sequential TEC/CloB2A2..."

Post-transplantation • Retrospective data • Acute Graft versus Host Disease • Acute Myelogenous Leukemia • Acute Respiratory Distress Syndrome • Chronic Graft versus Host Disease • Graft versus Host Disease • Hematological Malignancies • Immunology • Infectious Disease • Leukemia • Novel Coronavirus Disease • Oncology • Respiratory Diseases • Septic Shock • Transplantation

Up-Front Matched Unrelated Donor Transplantation in Pediatric Patients with Idiopathic Aplastic Anemia: A Phase II Feasibility Study, on Behalf of Société Francophone De Greffe De Moelle Et De Thérapie Cellulaire (SFGM-TC) and French Reference National Center of Severe Aplastic Anemia (ASH 2024) - "Conditioning regimen was fludarabine (30mg/m2/d) and cyclophosphamide (30mg/m2/d) D-6 to D-3 and either anti-thymoglobuline (Genzyme, France) 15mg/kg TD or total body irradiation 2Gy + ATG 7,5mg/kg TD depending on the age, below 14y or above. GvHD prophylaxis was ciclosporine A from D-1 to D365 associated to methotrexate 8mg/m2 D+1,+3 and+6...Finally, up-front HSCT from MUD for pts below the age of 18y presenting with SAA appears safe when the donor is available within 75-90 days. Rituximab is mandatory to lower the risk of EBV-PTLD for both prophylaxis and early pre-emptive treatment.If the donor recruitment is delayed, immune-suppressive therapy has to be preferred and promptly started."

Clinical • P2 data • Acute Graft versus Host Disease • Anemia • Aplastic Anemia • Bone Marrow Transplantation • Chronic Graft versus Host Disease • Graft versus Host Disease • Hematological Disorders • Immunology • Infectious Disease • Pediatrics • Transplantation

BISPECIFIC ANTIBODIES FOLLOWED BY ALLOGENEIC HEMATOPOIETIC STEM CELL TRANSPLANTATION AS RESCUE THERAPY IN REFRACTORY/RELAPSE NON-HODGKIN LYMPHOMA (SIE 2025) - "Eight pts (4 females and 4 males) with RR lymphomas (4 DLBCL, 3 FL and 1 MCL) received HSCT after treatment with glofitamab (4 pts), mosunetuzumab (3 pts) and epcoritamab (1 pts)...Most pts (7/8, 87%) received matched unrelated donors' transplants with TCF (Thiotepa, cyclophosphamide and fludarabine) conditioning regimen and ATG thymoglobuline as GVHD prophylaxis (Table 1)...Six pts achieved CR after steroid treatment while one pts progressed and died due to hepatic aGVHD refractory to steroid and ruxolitinib...This pts rapidly suspended immunosuppressive therapy without aGVHD reactivation and is still alive after venetoclax savage therapy...Table 1. Patient characteristics."

Acute Graft versus Host Disease • Bone Marrow Transplantation • Diffuse Large B Cell Lymphoma • Graft versus Host Disease • Hematological Malignancies • Hepatology • Immunology • Infectious Disease • Lymphoma • Non-Hodgkin’s Lymphoma • Pneumonia • Respiratory Diseases • Septic Shock • Transplantation

Prevention of CMV and BKV in De Novo Kidney Transplant Recipients Immunosuppressed with the Combination of Low Dose Tacrolimus and Everolimus (WTC 2025) - "Thymoglobuline induction was given to both the study groups... In conclusion, our data show the safety and efficacy of long-term immunosuppression in renal transplant recipients treated with the combination of EVR plus low dose TAC. We found significantly lower CMV and BK virus infections and significantly lower acute rejection in the EVE + low dose TAC group, respect to the standard TAC plus MMF immunosuppression."

Clinical • Cytomegalovirus Infection • Infectious Disease • Nephrology • Transplant Rejection • Transplantation

OPTIMIZED CONDITIONING REGIMEN ENHANCES TCRαß+ CELL DEPLETED HEMATOPOIETIC STEM CELL TRANSPLANTATION ENGRAFTMENT IN PATIENTS WITH THALASSEMIA MAJOR (EHA 2025) - ".Conditioning Regimens: The conditioning regimens were divided into two groups: TDH-A Group: Anti-thymocyte globulin (ATG) administered on days -8 to -7 without cyclophosphamide (Cy) on days - and/or -1; and TDH-B Group: ATG administered on days - 1 to -19 with 50mg/kg Cy on day - and/or an additional 5mg/kg Cy on day -1.Other conditioning steps were identical: - Days - 1 to -19: Thymoglobuline (rATG Sanofi France) 5mg/kg...- Days -6 to -4: Busulfan 90-100mg/m² (adjusted to maintain steady-state serum levels of 500-700 mg/L). - Days -6 to - : Fludarabine 40mg/m². - Day -3: Thiotepa 10mg/kg...GVHD Prophylaxis: Short-term (<6 months) low-dose tacrolimus or sirolimus with or without mycophenolate mofetil... ATG exhibits a bidirectionality of influences on engraftment dependent on timing. Pre-d0 (transplant day) ATG administration enhances engraftment while post-d0 use impairs it. Advancing ATG to day - 1 significantly promoted engraftment.Pre-transplant DLI..."

Clinical • Acute Graft versus Host Disease • Beta-Thalassemia • Bone Marrow Transplantation • Chronic Graft versus Host Disease • Genetic Disorders • Graft versus Host Disease • Hepatology • Immunology • Transplantation

Study of efficacy and safety of eltrombopag in combination with rabbit anti-thymocyte globulin and cyclosporine A in treatment naive East-Asian patients with severe aplastic anemia (clinicaltrialsregister.eu) - P2 | N=36 | Sponsor: Novartis

New P2 trial • Anemia • Aplastic Anemia • Hematological Disorders

Allograft-Educated Platelets for Gene Profiling of Acute Rejection After Heart Transplantation (ISHLT 2025) - P | "The recipients received induction with thymoglobuline, followed by tacrolimus, mycophenolic mofetil, and prednisolone maintenance immunosuppression...Initial findings also show that platelet gene expression profiling can accurately detect occurrence and severity of acute cellular rejection following heart transplantation (Figure 1).Conclusion This study proposes a novel approach to diagnosing acute rejection in heart transplant recipients. By directly comparing dd-cfDNA levels and the platelet transcriptome with EMB transcriptomics, the research aims to confirm the efficacy of non-invasive methods, improve diagnostic accuracy, reduce patient burden from surveillance EMB, and enhance long-term outcomes in heart transplantation."

Oncology • Transplant Rejection • Transplantation

BISPECIFIC ANTIBODIES FOLLOWED BY ALLOGENEIC HEMATOPOIETIC STEM CELL TRANSPLANTATION AS RESCUE THERAPY IN REFRACTORY/RELAPSED NON-HODGKIN LYMPHOMA: REAL-LIFE EXPERIENCE IN CART AND TARGET THERAPY ERA (EBMT 2025) - " Six patients (4 females and 2 males) with RR lymphomas (3 follicular lymphomas, 2 diffuse B-cell lymphomas and 1 mantle cell lymphoma) received HSCT after treatment with mosunetuzumab (3 pts) or glofitamab (3 pts)...Pts received a median of 8 (4-12) doses (cycles) of BiAb; 4 pts had previously progressed after CAR-T cell therapy (4 Tisagenlecleucel, 1 Brexucbtagene autoleucel) while 2 pts were refractory to target therapy...One pts received haploidentical transplant with post- cyclophosphamide GVHD prophylaxis while 5 pts received matched unrelated donors' transplants with GVHD prophylaxis based on ATG thymoglobuline...Five patients were treated with steroid: 4 patients achieved CR while the other one died due to hepatic aGVHD despite refractory to steroid and ruxolitinib... in our experience, bridging with BiAb to HSCT in 6 pts who failed CAR-T or target therapies achieved a response in all pts before transplant and allowed a safe HSCT with only 1 NRM event and..."

Clinical • Acute Graft versus Host Disease • B Cell Lymphoma • Bone Marrow Transplantation • Chronic Graft versus Host Disease • Diffuse Large B Cell Lymphoma • Follicular Lymphoma • Graft versus Host Disease • Hematological Malignancies • Hepatology • Immunology • Infectious Disease • Lymphoma • Mantle Cell Lymphoma • Non-Hodgkin’s Lymphoma • Novel Coronavirus Disease • Oncology • Pneumonia • Respiratory Diseases • Septic Shock • Transplantation

BISPECIFIC ANTIBODIES FOLLOWED BY ALLOGENEIC HEMATOPOIETIC STEM CELL TRANSPLANTATION AS RESCUE THERAPY IN REFRACTORY/RELAPSED NON-HODGKIN LYMPHOMA: REAL-LIFE EXPERIENCE IN CART AND TARGET THERAPY ERA (EBMT 2025) - " Six patients (4 females and 2 males) with RR lymphomas (3 follicular lymphomas, 2 diffuse B-cell lymphomas and 1 mantle cell lymphoma) received HSCT after treatment with mosunetuzumab (3 pts) or glofitamab (3 pts)...Pts received a median of 8 (4-12) doses (cycles) of BiAb; 4 pts had previously progressed after CAR-T cell therapy (4 Tisagenlecleucel, 1 Brexucbtagene autoleucel) while 2 pts were refractory to target therapy...One pts received haploidentical transplant with post- cyclophosphamide GVHD prophylaxis while 5 pts received matched unrelated donors' transplants with GVHD prophylaxis based on ATG thymoglobuline...Five patients were treated with steroid: 4 patients achieved CR while the other one died due to hepatic aGVHD despite refractory to steroid and ruxolitinib... in our experience, bridging with BiAb to HSCT in 6 pts who failed CAR-T or target therapies achieved a response in all pts before transplant and allowed a safe HSCT with only 1 NRM event and..."

Clinical • Acute Graft versus Host Disease • B Cell Lymphoma • Bone Marrow Transplantation • Chronic Graft versus Host Disease • Diffuse Large B Cell Lymphoma • Follicular Lymphoma • Graft versus Host Disease • Hematological Malignancies • Hepatology • Immunology • Infectious Disease • Lymphoma • Mantle Cell Lymphoma • Non-Hodgkin’s Lymphoma • Novel Coronavirus Disease • Oncology • Pneumonia • Respiratory Diseases • Septic Shock • Transplantation

DOES THE TIME OF ANTI-THYMOCYTE GLOBULIN ADMINISTRATION AFFECT UNRELATED DONOR ALLO-HCT OUTCOMES? A RETROSPECTIVE ANALYSIS ON BEHALF OF THE POLISH ADULT LEUKEMIA GROUP (EBMT 2025) - "Background: Rabbit anti-thymocyte globulin (r-ATG) has a pivotal role in preventing graft-versus-host disease (GvHD) in unrelated allo-HCT. Thymoglobuline (ATG-T, formerly Genzyme) forms one of the most widely utilized r-ATG formulations... Our findings suggest that the ATG-T administration scheme and ATG-T exposure may significantly influence allo-HCT outcomes. The prolonged ATG-T persistence after donor T-cell infusion in the ATG-Tf group, which likely led to greater donor T-cell depletion, resulted in a significantly lower incidence of aGvHD and higher 5-year OS compared to ATG-Tp with similar infection rates and conditioning regimens.Given the limitations of our study, including a small sample size and donor type heterogeneity, these results warrant confirmation in larger, prospective, double-blind randomized trials with more homogeneous cohorts. The retrospective nature of this study and involvement of historical groups of patients treated when PTCy was not as..."

Retrospective data • Acute Graft versus Host Disease • Acute Lymphocytic Leukemia • Chronic Graft versus Host Disease • Graft versus Host Disease • Hematological Malignancies • Immunology • Infectious Disease • Leukemia • Oncology • CD34

DOES THE TIME OF ANTI-THYMOCYTE GLOBULIN ADMINISTRATION AFFECT UNRELATED DONOR ALLO-HCT OUTCOMES? A RETROSPECTIVE ANALYSIS ON BEHALF OF THE POLISH ADULT LEUKEMIA GROUP (EBMT 2025) - "Background: Rabbit anti-thymocyte globulin (r-ATG) has a pivotal role in preventing graft-versus-host disease (GvHD) in unrelated allo-HCT. Thymoglobuline (ATG-T, formerly Genzyme) forms one of the most widely utilized r-ATG formulations... Our findings suggest that the ATG-T administration scheme and ATG-T exposure may significantly influence allo-HCT outcomes. The prolonged ATG-T persistence after donor T-cell infusion in the ATG-Tf group, which likely led to greater donor T-cell depletion, resulted in a significantly lower incidence of aGvHD and higher 5-year OS compared to ATG-Tp with similar infection rates and conditioning regimens.Given the limitations of our study, including a small sample size and donor type heterogeneity, these results warrant confirmation in larger, prospective, double-blind randomized trials with more homogeneous cohorts. The retrospective nature of this study and involvement of historical groups of patients treated when PTCy was not as..."

Retrospective data • Acute Graft versus Host Disease • Acute Lymphocytic Leukemia • Chronic Graft versus Host Disease • Graft versus Host Disease • Hematological Malignancies • Immunology • Infectious Disease • Leukemia • Oncology • CD34

FERTILITY OUTCOMES AFTER FLUDARABINE/BUSULFAN AND ANTITHYMOCYTE GLOBULIN AS REDUCED TOXICITY MYELOABLATIVE CONDITIONING FOR MATCHED RELATED DONOR ALLO-HCT : EXPERIENCE FROM EHU 1ER NOVEMBER D'ORAN, ALGERIA (EBMT 2025) - "This study aims to evaluate the reproductive health of allogeneic HCT patients who received myeloablative (MAC) reduced toxicity conditioning (RTC) regimen busulfan, fludarabine thymoglobuline (FB4 +ATG) in our center... The MAC RTC regimen (FB4 + ATG) has shown potential in preserving fertility in a quarter of patients, particularly in men, and is associated with an excellent quality of life. However, to enhance the support provided to these patients, it is important to implement comprehensive care strategies, including regular monitoring of hormonal levels, fertility counseling, and psychological support. Additionally, these findings need to be confirmed through a larger-scale study in the same region to confirm the results and explore broader implications for patient care."

Hematological Disorders

ALLOGENIC HEMATOPOIETIC STEM CELL TRANSPLANTATION AND 12-YEARS FOLLOW-UP IN TWO SIBLINGS AFFECTED BY FUCOSIDOSIS (EBMT 2025) - "At the age of 25 months, he received as conditioning fludarabine, targeted busulfan and thymoglobuline and as GVHD-prophylaxis CSA and MMF...Unfortunately, the graft did not engraft and re-HSCT was performed 2 months later using a re-conditioning with Fludarabin, Treosulfan und Thymoglobulin and a male HLA 7/12 UCD.Patient 2 was neurologically asymptomatic prior HSCT...​ Patient 1 developed shortly after re-/HSCT multiple complications, such as central catheter infection, viral reactivations and GvHD of the skin, gut and liver, which required immunosuppression with Infliximab and steroids... In the literature there is a lack of data on long term outcomes after HSCT in fucosidosis patients. Our patients showed an high level of donor cell engraftment and no signs of chronic GvHD. Over the years a progression of myelination was observed in MRI, showing that early HSCT in fucosidosis can modulate and positively affect neurological decay in this devastating disease."

Bone Marrow Transplantation • Chronic Graft versus Host Disease • CNS Disorders • Graft versus Host Disease • Immunology • Infectious Disease • Lysosomal Storage Diseases • Metabolic Disorders • Rare Diseases • Transplantation

ALLOGENIC HEMATOPOIETIC STEM CELL TRANSPLANTATION AND 12-YEARS FOLLOW-UP IN TWO SIBLINGS AFFECTED BY FUCOSIDOSIS (EBMT 2025) - "At the age of 25 months, he received as conditioning fludarabine, targeted busulfan and thymoglobuline and as GVHD-prophylaxis CSA and MMF...Unfortunately, the graft did not engraft and re-HSCT was performed 2 months later using a re-conditioning with Fludarabin, Treosulfan und Thymoglobulin and a male HLA 7/12 UCD.Patient 2 was neurologically asymptomatic prior HSCT...​ Patient 1 developed shortly after re-/HSCT multiple complications, such as central catheter infection, viral reactivations and GvHD of the skin, gut and liver, which required immunosuppression with Infliximab and steroids... In the literature there is a lack of data on long term outcomes after HSCT in fucosidosis patients. Our patients showed an high level of donor cell engraftment and no signs of chronic GvHD. Over the years a progression of myelination was observed in MRI, showing that early HSCT in fucosidosis can modulate and positively affect neurological decay in this devastating disease."

Bone Marrow Transplantation • Chronic Graft versus Host Disease • CNS Disorders • Graft versus Host Disease • Immunology • Infectious Disease • Lysosomal Storage Diseases • Metabolic Disorders • Rare Diseases • Transplantation

ALLOGENEIC STEM CELL TRANSPLANTATION FOR PHILADELPHIA CHROMOSOME POSITIVE ACUTE LYMPHOBLASTIC LEUKEMIA (EBMT 2025) - "Three types of Busulfan-based conditioning regimen were used: Busulfan-Aracytine-Melphalan for 12 pts, Busulfan-cyclophosphamide-Etoposide for 15 pts, and Busulfan-Cyclophosphamide for 6 pts. For haplo-identical transplant, Busulfan-Aracytine-Cyclophosphamide and Thymoglobuline (Beijing Protocol) in 5 pts, Busulfan-Fludarabine-Thiotepa (TBF) in 15 pts...GVHD prophylaxis consisted on association of ciclosporine-methotrexate (HLA-identical sibling), ciclosporine-methotrexate-MMF (Beijing Protocol), and ciclosporine-MMF-PTCy (TBF)... Allo-HSCT after a chemotherapy-alone conditioning regimen with TKIs have improved outcomes for pts with Ph+ ALL. Despite the use TKIs, we note à high rate of relapse. The advent of immunotherapy improves the results of transplantation due to better control of minimal residual disease."

Acute Graft versus Host Disease • Acute Lymphocytic Leukemia • B Acute Lymphoblastic Leukemia • Bone Marrow Transplantation • Chronic Graft versus Host Disease • Graft versus Host Disease • Hematological Disorders • Hematological Malignancies • Hepatology • Immunology • Infectious Disease • Leukemia • Oncology • Pancreatitis • Transplantation • CD34

Cytomegalovirus infection in the first year after pediatric renal transplantation: A single center experience (IPNA 2025) - "Aims/Purpose Cytomegalovirus (CMV) infection is a frequent complication in pediatric kidney transplant (KT): Valganciclovir (VCG) is indicated for both prophylaxis and treatment...Immunosuppression regime included Basiliximab or Thymoglobuline (ATG) for induction, followed by Calcineurin inhibitors (CNIs), Mycophenolate (MMF) or Azathioprine (AZA) and Prednisone (PDN) for maintenance...Since the early-onset of infection in the high-risk group, it should be preferred a longer prophylaxis. Moreover, it could be hypothesized to include the medium-high risk group, especially the youngers, in the prophylaxis indication due to their major rate of infection."

Clinical • Cardiovascular • Cytomegalovirus Infection • Hematological Disorders • Infectious Disease • Nephrology • Pediatrics • Renal Disease • Thrombosis • Transplant Rejection • Transplantation

Evaluation of 3 Different Doses of IV Busulfan (clinicaltrials.gov) - P2 | N=177 | Active, not recruiting | Sponsor: Institut Paoli-Calmettes | Unknown status ➔ Active, not recruiting | Trial completion date: Dec 2018 ➔ Jul 2026 | Trial primary completion date: Dec 2018 ➔ Jul 2026

Enrollment closed • Trial completion date • Trial primary completion date • Acute Myelogenous Leukemia • Bone Marrow Transplantation • Hematological Malignancies • Leukemia • Myelodysplastic Syndrome • Oncology • Transplantation

INFECTIOUS COMPLICATIONS IN PATIENTS UNDERGOING ALLOGENEIC STEM CELL TRANSPLANTATION (HSCT) FOR ACUTE MYELOID LEUKEMIA AFTER CPX-351 TREATMENT: A "REAL-LIFE" MULTICENTER RETROSPECTIVE EXPERIENCE BY THE SEIFEM GROUP (SIE 2024) - "Most pts (56%) underwent conditioning with TBF-based regimens (Thiotepa, Busulfan and Fludarabine). GvHD prophylaxis schedules mostly included cyclophosphamide combined with mycophenolic acid and/or cyclosporine (53%) or thymoglobuline and methotrexate (30%)...We therefore confirmed the efficacy of CPX-351 in inducing prolonged survival in high-risk patients. Figure 1."

Retrospective data • Acute Myelogenous Leukemia • Bone Marrow Transplantation • Graft versus Host Disease • Hematological Malignancies • Immunology • Infectious Disease • Leukemia • Oncology • Pneumonia • Respiratory Diseases • Transplantation

A Comparative Analysis of Low Dose Grafalon® Versus Thymoglobuline® as Serotherapy in Hematopoietic Stem Cell Transplant in Pediatric and Young Adult Population. (PubMed, Pediatr Hematol Oncol) - "Due to the shift of donor preference to alternate donors, reliance on rabbit-ATG (rATG) has increased. In our study, Grafalon® tended to have better OS, decreased incidence of acute grade III-IV GvHD, and extensive cGVHD. There was no difference in engraftment kinetics, PGF, and immune reconstitution between 2 cohorts of serotherapy."

Journal • Bone Marrow Transplantation • Chronic Graft versus Host Disease • Graft versus Host Disease • Hematological Disorders • Immunology • Pediatrics • Transplantation

Are intravenous immunoglobulins effetive in preventing primary EBV infection in pediatric kidney transplant recipient? (ESPN 2024) - "All children received basiliximab/ thymoglobuline and steroids as induction, and then calcineurin inihibitor with mycophenolate mofetil/ mTOR inhibitor and steroid... Despite the small number of patients, our data do not seem to support the use of IGIV as a tool to prevent EBV primary infection in pediatric R- who receive the graft from D+."

Clinical • Epstein-Barr Virus Infections • Infectious Disease • Pediatrics • Transplantation

Predictive indicators for graft survival in pediatric kidney transplantation: a comprehensive analysis over ten years in our single center experience (ESPN 2024) - "In this study, factors that did not influence graft function over time were: gender of recipient (p =0.123) or donor (p =0.381), pre-emptive (p =0.45), time on waiting list (p =0.28), living donor (p =0.0175) versus deceased donor (p =0.017), number of previous transplants (p =0.27), presence of acute tubular necrosis (p =0.67), previous blood transfusions (p =0.12), donor or recipient of cytomegalovirus status (p =0.41 and p =0.89, respectively), ABO-identical matching (p =0.26) or use of Thymoglobuline versus non-use of Thymoglobuline (p =0.18)... Understanding prognostic factors in pediatric kidney transplants is vital for optimal outcomes. This study identifies donor age as a negative predictor of long-term survival. Insights inform decision-making and underscore resource needs."

Clinical • Cytomegalovirus Infection • Pediatrics • Transplantation • HLA-B

Early vascular rejection not associated with anti-HLA antibodies with good medium and long term prognosis. Cases report (ESPN 2024) - "Induction: basiliximab, steroids, MMF and IV cyclosporine...Anti-rejection treatment: switch to tacrolimus, high-dose steroids, plasma exchange, immunoglobulins, rituximab and bortezomib...Anti-rejection treatment: high-dose steroids, plasma exchanges, thymoglobuline and rituximab... Our patients share common clinical (very early presentation, severe hypertension) and pathological (endarteritis, macrophagic infiltrate) findings. We could not demonstrate an antibody-mediated mechanism. Despite severe presentation, prompt and aggresive treatment led to significant improvement in renal outcome."

Case report • Clinical • ANCA Vasculitis • Cardiovascular • Hypertension • Nephrology • Renal Disease • Vasculitis